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ABSTRACT
In the Systolic Blood Pressure Intervention Trial (SPRINT), intensive blood pressure (BP) 
lowering was associated with significant reduction in composite cardiovascular (CV) 
outcomes in hypertension. Subsequently, several meta-analyses have corroborated the 
findings from SPRINT and these benefits were more prominent in subjects with higher 
cardiovascular risk at baseline. As such, the recent American College of Cardiology (ACC)/
American Heart Association (AHA) hypertension guideline and the European Society of 
Hypertension (ESH)/European Society of Cardiology (ESC) guideline recommended the 
lowering of target BP to less than 130/80 mmHg in most hypertensive subjects. However, one 
should keep in mind the potential harm of too much BP lowering. Post hoc analysis of clinical 
trials have demonstrated increased cardiovascular mortality and events with too much BP 
lowering. Therefore, although intensive BP lowering may be beneficial in further reducing 
CV outcomes, too much reduction below 120/70 mmHg may actually harmful. In conclusion, 
although intensive BP lowering to achieve target BP below 130/80 mmHg is beneficial in 
reducing CV outcomes, one should do so cautiously as to avoid adverse events. As such, the 
first target of anti-hypertensive treatment should be to achieve BP lowering below 140/90 
mmHg. Once that target is achieved, one could target BP below 130/80 mmHg keeping in 
mind to avoid signs of organ hypoperfusion such as orthostatic hypotension, orthostatic 
dizziness, weakness and serum creatinine elevation.
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INTRODUCTION
Recent changes in the American and European guidelines on the management of arterial 
hypertension have resulted in emphasis of intensive blood pressure (BP) lowering below 
130/80 mmHg for most hypertensive patients.1)2) The 2017 American College of Cardiology 
(ACC)/American Heart Association (AHA)/American Society of Hypertension (ASH) 
hypertension guideline recommended that treatment goal of all hypertensive patients should 
be lowered to below 130/80 mmHg and that high risk patients with stage 1 hypertension, 
whose BP is between 130/80 to <140/90 mmHg with ASVD risk score of more than 10% or 
cardiovascular disease (CVD), should be considered for drug treatment.1) The 2018 European 
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Ideal Target Blood Pressure in 
Hypertension
guideline recommends a strict target systolic blood pressure (SBP) goal of at or below 
130 mmHg for most hypertensive patients except for those with chronic kidney disease 
(CKD) and elderly over the age of 65 and recommended that diastolic blood pressure (DBP) 
should be controlled to between 70–80 mmHg.2) Similarly, in the 2018 Korean Society of 
Hypertension guidelines for the management of hypertension, a target SBP of 130 mmHg was 
recommended for high risk hypertensive patients such as hypertensive patients associated 
with coronary artery disease, congestive heart failure, CKD with proteinuria and diabetes 
mellitus with CVD.3) In this review, we will discuss the evidence that serves as the basis for 
these recent changes in target BP.
ESTABLISHMENT OF TARGET BLOOD PRESSURE 
OF 140/90 MMHG AS TREATMENT TARGET IN 
HYPERTENSION
Although we take for granted the efficacy of anti-hypertensive treatment in preventing 
cardiovascular (CV) events, the establishment of the current recommendations of BP 
targets have a long history. Before the publication of the seminal Veterans Administration 
Cooperative Study (VA Cooperative Study) in 1967, the only evidence of benefit for treating 
hypertension was above the level of what we would today consider to be severe, emergent 
hypertension. The VA Cooperative study enrolled 143 male hypertensive patients with 
DBP between 115–129 mmHg, patients whose DBP levels were thought to be mild forms of 
hypertension at that time and randomized them to active treatment versus placebo. The 
clear benefits of active treatment demonstrated in this study paved the way for clinical trials 
in the 1970s and 1980s that established 140/90 mmHg as the target BP in hypertension.4) 
In the 2nd VA cooperative study on the effects of treatment on morbidity in hypertension, 
380 male hypertensive patients with DBP between 90–114 mmHg were randomized to 
active treatment and control. The results, for the first time, demonstrated that BP lowering 
in hypertensive patients with DBP above 90 mmHg was beneficial in reducing CV events 
and mortality.5) Subsequent studies such as the Hypertension detection and follow-up 
program I, Hypertension-Stroke Cooperative Study, Australian Therapeutic Trial in Mild 
Hypertension and Medical Research Council (MRC) trial of mild hypertension enrolled 
hypertensive subjects with DBP above 90 mmHg and demonstrated the beneficial effect 
of anti-hypertensive treatment in reducing CV events.6-9) As such, the diagnostic threshold 
of hypertension was established as BP above 140/90 mmHg based on the definition of 
hypertension being the level of BP above which the benefits of treatment unequivocally 
outweighs the risks of treatment.2) Also, a therapeutic target of BP below 140/90 mmHg was 
established as well.
RECOMMENDATION FOR INTENSIVE BLOOD PRESSURE 
LOWERING IN PATIENTS WITH DIABETES MELLITUS AND 
CHRONIC KIDNEY DISEASE
The first clinical trial to determine whether further intensive lowering of BP reduces CV 
outcomes was the hypertension optimal treatment (HOT) study.10) In this study, 18,790 
patients age 50–80 with baseline DBP of 100–115 mmHg were randomized to target DBP of 
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≤90, ≤85, and ≤80 mmHg. Overall, there was no significant difference in CV events among 
the three treatment arms with the lowest incidence of major CV events occurring at mean 
achieved DBP of 82.6 mmHg. However, in 1,501 patients with diabetes mellitus, there was a 
51% reduction in major CV events in the DBP ≤80 mmHg treatment target arm compared to 
the DBP ≤90 mmHg arm.10)
For patients with CKD, the modification of diet in renal disease (MDRD) randomized 840 
patients with non-diabetic chronic renal disease to usual BP treatment target (mean BP, 107 
mmHg) versus intensive BP target (mean BP, 92 mmHg). The study showed that in subjects 
with proteinuria of more than 1 g/day, intensive BP lowering was associated with significantly 
slower decline in the glomerular filtration rate.11) In 2003, based on the above mentioned 
evidence, the JNC 7 recommended a treatment target BP of 140/90 mmHg and BP goal of less 
than 130/80 mmHg for patients with diabetes and chronic renal disease.12)
REVISION OF TARGET BLOOD PRESSURE TO 140/90 
MMHG FOR ALL HYPERTENSIVE PATIENTS REGARDLESS 
OF ASSOCIATED CONDITIONS
The recommendation put forth by the JNC 7 was generally accepted until the publication of 
the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study in 2010, which was 
the first study to explore the benefits of intensive BP lowering specifically in patients with 
diabetes mellitus.13) Although strict BP lowering had been recommended for hypertensive 
patients with diabetes, it was based on a subgroup analysis from the HOT trial and expert 
consensus that high risk hypertensives needed to be treated with more intensive BP lowering. 
The ACCORD study randomized 4,733 to either intensive SBP lowering (<120 mmHg) 
or standard BP lowering (<140 mmHg) with a mean follow up of 4.7 years. Surprisingly, 
intensive BP lowering did not reduce the rate of a composite of fatal and non-fatal CV 
outcome while reducing the rate of fatal or non-fatal stroke.13) For CKD, the evidence for 
benefit of intensive BP lowering was also unclear. In both the Blood-pressure Control for 
Renoprotection in Patients with Non-diabetic Chronic Renal Disease (REIN-2) study and 
the African-American Study of Kidney Disease and Hypertension (AASKD), intensive BP 
control failed to show benefit in slowing the progression of kidney disease.14)15) Based on 
these evidence, both the 2013 European Society of Hypertension (ESH)/European Society of 
Cardiology (ESC) arterial hypertension guideline and the 2014 JNC 8 guideline recommended 
that regardless of associated conditions, the target BP should be 140/90 mmHg with the 
European guideline recommending a target DBP of 85 mmHg for subjects with diabetes 
mellitus.16)17)
BACK TO 130/80 MMHG: INTENSIVE BLOOD PRESSURE 
TREATMENT TARGET FOR ALL HYPERTENSIVES
In 2015, the publication of the Systolic Blood Pressure Intervention Trial (SPRINT) changed 
the landscape of the hypertension treatment guideline.18) The objective of the study was to 
determine whether intensive SBP lowering below 120 mmHg lowers the risk of CV outcomes 
compared to conventional SBP lowering below 140 mmHg in individuals with SBP above 
130 mmHg without diabetes. The 9,361 persons enrolled in the study were relatively high 
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risk, with the inclusion criteria of the SPRINT study being individuals above the age of 50 
with at least 1 of the following: 1) history of clinical/subclinical CVD, excluding stroke, 
2) Framingham risk score of more than 15, 3) age of 75 years of age or more 4) CKD with 
estimated glomerular filtration rate between 20–60 mL/min/1.73 m2. The clinical trial was 
stopped after a median follow-up of 3.26 years due to the significant, 25% lowering of the 
primary composite outcome in the intensive treatment group compared to the standard 
treatment group (hazard ratio [HR] with intensive treatment, 0.75; 95% confidence interval 
[CI], 0.64–0.89; p=0.003).18) One thing to keep in mind for the SPRINT study was that 
unattended automated office blood pressure (AOBP) measurement was used for clinical 
office BP measurement. As studies have shown that AOBP is 5–15 mmHg lower than usual 
office BP measurements, AOBP SBP target of 120 mmHg would most likely corresponded to 
usual clinical office SBP of 130 mmHg.19)20)
Subsequently, meta-analysis of BP lowering clinical trials have demonstrated the benefit of 
intensive BP lowering. In a recent meta-analysis of 123 BP lowering intervention studies with 
613,815 participants, Ettehad et al.21) demonstrated the every 10 mmHg reduction in SBP is 
associated with 20% reduction in the risk of major CV events, 17% reduction in the risk of 
coronary heart disease, 27% reduction in the risk of stroke 28% reduction in the risk of heart 
failure and 13% reduction in all-cause mortality. The proportion risk reduction did not differ 
for those with lower baseline SBP of less than 140 mmHg, suggesting that there is further 
benefit in reducing SBP to less than 130 mmHg.21) Also, the benefits of intensive BP lowering 
in high risk patients were demonstrated in a meta-analysis by Xie et al.,22) in which 19 clinical 
trials including 44,989 patients were analyzed. In this meta-analysis, the average CV event 
rate was approximately 0.9%/year, corresponding to 9–10%/10 year and the average BP of 
the intensive BP lowering arm and the usual treatment arm was 133/76 mmHg versus 140/81 
mmHg, respectively. The results showed that intensive BP lowering was associated with 14% 
reduction in CV events, 13% reduction in MI, 22% reduction in stroke, 10% reduction in 
albuminuria and 19% reduction in retinopathy progression without any significant reduction 
in heart failure, CV death, total mortality, or end-stage renal disease.22) Finally, Thomopoulos 
et al.23) performed a meta-analysis of randomized controlled trials of BP lowering treatment 
published between 1966 and 2015. Among the trials comparing the effects of more intense 
BP lowering versus less intense BP lowering, the standardized relative risk of SBP lowering of 
10 mmHg in achieved SBP of <130 mmHg in the more intense group BP lowering group was 
associated with 21% reduction of stroke. For the standardized relative risk of DBP lowering of 5 
mmHg in achieved DBP of <80 mmHg in the more intense BP lowering group, there was a 27% 
reduction in stroke and 27% reduction in CV death. Additional analysis comparing the effects 
of more intense BP lowering versus placebo or less intense BP lowering, the standardized 
relative risk of SBP lowering of 10 mmHg in achieved SBP of <130 mmHg in the more intense 
BP lowering group was associated with 21% reduction of stroke, 14% reduction of coronary 
heart disease, and 20% reduction in CV death.23) Taken together, the evidence strongly 
suggests that intensive BP lowering reduces CV events, especially in those at high CV risk.
One thing to keep in mind is that since most of the clinical trials for BP lowering have been 
performed in subjects with high CV risk, there is some limitation to generalize the results 
from the clinical trials to all hypertensive subjects. Recently, Lee et al.24) analyzed 148,761 
low risk, treated stage 1 hypertensive subjects from the National Health Insurance Service 
Health Examination Database. The results showed that the lowest adjusted risk of all-cause 
mortality was observed in subjects with average SBP of 120 to <130 mmHg and average DBP 
of 70 to <80 mmHg, which is in line with the target BP recommendation of the newest ACC/
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AHA and ESH/ESC arterial hypertension guideline and supports the generalization of the 
recommended target BP in the general hypertensive population.24)
BLOOD PRESSURE TARGET IN THE ELDERLY
The efficacy of anti-hypertensive treatment in reducing CV events in the elderly was 
established after the publication of the Systolic Hypertension in the Elderly Program (SHEP), 
the Systolic Hypertension in Europe (Syst-Eur) Trial and the Systolic Hypertension in China 
(Syst-China) trial.25-27) The enrollment criteria of these 3 clinical trials was hypertensive 
subjects over age 60 with SBP between 160–219 mmHg and DBP below 90 mmHg for SHEP 
and DBP below 95 mmHg for Syst-Eur and Syst-China trials and the achieved SBP for the 
active treatment group was between 140–150 mmHg for all 3 trials. For the very elderly, 
defined as hypertensive subjects over the age of 80, the Hypertension in the Very Elderly Trial 
(HYVET) demonstrated that for subjects with baseline SBP ≥160 mmHg, active treatment 
was associated with significant reduction in fatal or non-fatal stroke, stroke mortality, CV 
mortality, and heart failure. The achieved SBP in the HYVET trial was also between 140–150 
mmHg.28) However, both the Japanese Trial to Assess Optimal Systolic Blood Pressure in the 
Elderly Hypertensive Patients (JATOS) and Valsartan in Elderly Isolated Systolic Hypertension 
study failed to demonstrate the benefit of lowering SBP below 140 mmHg in the elderly.29)30) 
As such, the target SBP in the elderly in the major clinical guidelines remained at 150 mmHg 
until most recently.16)17)
This all changed with the publication of the SPRINT trial. In the SPRINT elderly trial, 
which analyzed the results from 2,636 participants in the SPRINT trial who were over 
the age of 75, intensive SBP lowering (SBP target <120 mmHg) was associated with 34% 
reduction in primary composite outcome compared to the standard SBP lowering(SBP 
target <140 mmHg).31) Based on these results, the ACC/AHA arterial hypertension guideline 
recommended a target SBP <130 mmHg for elderly hypertensive patients.1) However, 
because the achieved BP in the SPRINT elderly trial was 124/62 mmHg versus 135/67 mmHg 
and because unattended automatic office BP measurement was used in the SPRINT study, 
both the 2018 ESH/ESC guideline and the 2018 Korean Society of Hypertension guideline 
suggested that the mean SBP of 124 mmHg in the intensive treatment arm more probably 
reflects a conventional office SBP between 130–139 mmHg and recommended a target SBP of 
130–140 mmHg in elderly hypertensive subjects above the age of 65.2)3)
CONSIDERING THE LOWER LIMITS OF BLOOD PRESSURE 
REDUCTION DURING INTENSIVE BLOOD PRESSURE 
LOWERING
The harmful effect of too much BP lowering, the J curve effect, has been a long-standing issue 
of debate. In a post hoc analysis of the International Verapamil-Trandolapril (INVEST) study, 
which was a randomized trial evaluation 22,576 patients with hypertension with coronary 
artery disease, Messerli et al found increased risk of MI in subjects who had lower DBP below 
70 mmHg. An interaction between lower DBP and history of revascularization was observed 
with relatively lower risk for primary outcomes in patients with lower DBP and history of 
revascularization compared to patients with lower DBP without history of revascularization.32) 
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These results were recently corroborated by a pooled analysis of the Ongoing Telmisartan 
Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) and Telmisartan 
Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease 
(TRANSCEND) trial.33) In this analysis, 30937 subjects at high CV risk were analyzed for CV 
outcomes according to the on treatment SBP and DBP. The results showed that on treatment 
SBP of less than 120 mmHg was associated with increased risk of composite CV outcome (HR, 
1.14; 95% CI, 1.03–1.26), CV death (HR, 1.29; 95% CI, 1.12–1.49), and all cause death (HR, 1.28; 
95% CI, 1.15–1.42) compared to subjects with on treatment SBP between 120–140 mmHg. Also, 
mean DBP below 70 mmHg was associated with increased risk of composite primary outcome 
(HR, 1.31; 95% CI, 1.20–1.42), MI (HR, 1.55; 95% CI, 1.33–1.80), hospitalization for heart failure 
(HR, 1.59; 95% CI, 1.36–1.86) and all-cause mortality (HR, 1.16; 95% CI, 1.06–1.28) compared 
to subjects with mean DBP 70–80 mmHg.33) Further supporting these findings was an analysis 
of 1,234,435 participants of the Korean Cancer Prevention Study cohort, in which the hazard 
ratios of mortality from atherosclerotic CVD was 1.37 (95% CI, 1.20–1.37) for those with DBP 
<60 mmHg compared to those with DBP of 70–79 mmHg.34) Taken together, although intensive 
BP lowering may be beneficial in further reducing CV outcomes, too much reduction below 
120/70 mmHg may actually be harmful. One should be especially careful in DBP going below 
70 mmHg in those with underlying multivessel coronary artery disease who did not undergo 
revascularization or in those with left ventricular hypertrophy.
Also, one should be aware that aggressive BP lowering may lead to increased risk of 
adverse events leading to treatment discontinuation. In a meta-analysis of 50 BP lowering 
randomized clinical trials which provided data on treatment discontinuation for adverse 
events and treatment associated serious adverse events, SBP/DBP reduction of 10/5 mmHg 
was associated with 24% reduction of major CV events and 89% increase in the risk of 
treatment discontinuation. Furthermore, SBP reduction below 130 mmHg was associated 
with smaller reduction in CV events with greater risk of adverse events resulting in treatment 
discontinuation.35) As adherence to medication is an important, but often forgotten factor 
for reducing CV events,36) one should make every effort to minimize adverse events, even if it 
means that the target BP is not below the current recommended levels.
CONCLUSION
Although intensive BP lowering to achieve target BP below 130/80 mmHg is beneficial in 
reducing CV outcomes, one should do so cautiously as to avoid adverse events. As such, the 
first target of anti-hypertensive treatment should be to achieve BP lowering below 140/90 
mmHg. Once that target is achieved, one could target BP below 130/80 mmHg keeping in 
mind to avoid signs of organ hypoperfusion such as orthostatic hypotension, orthostatic 
dizziness, weakness and serum creatinine elevation.
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